Verification evidence is still being completed.
PDF / print export
Herantis Pharma
Espoo, Finland
- Verified lead
- Antti Vuolanto
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- CEO
- 2026 technical specialization
- Neuroinflammation, CNS Therapeutics, Biologics Development, and Translational Drug Development
- Review cycle
- May 2026
- Full address
- Bertel Jungin aukio 1, FI-02600 Espoo, Finland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Herantis memorandum confirming the Espoo operating address and company profile.
- Editorial note
- Herantis is published because official investor and company materials confirm current leadership, Espoo operating footprint, and a clear therapeutics program in neurology and neuroinflammation.
Neuroinflammation, CNS Therapeutics, Biologics Development, and Translational Drug Development
Public-company investor disclosure, Official therapeutics pipeline description, Finnish operating-address disclosure
Herantis is published because official investor and company materials confirm current leadership, Espoo operating footprint, and a clear therapeutics program in neurology and neuroinflammation.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Espoo, Finland
Herantis Pharma
Neuroinflammation, CNS Therapeutics, Biologics Development, and Translational Drug Development · Clinical-stage biotech therapeutics platform
Herantis Pharma runs biologic therapeutics development, cns drug development, and translational neuroinflammation research in Espoo, Finland.
- Lead
- Antti Vuolanto (verified ↗)
- Address
- Bertel Jungin aukio 1, FI-02600 Espoo, Finland (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 21 Mar 2026 (2mo ago)
- Scale
- Clinical-stage biotech therapeutics platform
- Capabilities
- Biologic Therapeutics Development · CNS Drug Development · Translational Neuroinflammation Research
- Founded
- 2008
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Antti Vuolanto
CEO
Full addressBertel Jungin aukio 1, FI-02600 Espoo, Finland
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official Herantis company memorandum listing the Bertel Jungin aukio 1 Espoo address.
Open sourceClinical-stage biotech therapeutics platform
Espoo, Finland. Neuroinflammation, CNS Therapeutics, Biologics Development, and Translational Drug Development. Review completed on 21 Mar 2026.
Finnish corporate governance and biotech clinical-development oversight
Public-company investor disclosure, Official therapeutics pipeline description, Finnish operating-address disclosure
Neuroinflammation, CNS Therapeutics, Biologics Development, and Translational Drug Development
Herantis is published because official investor and company materials confirm current leadership, Espoo operating footprint, and a clear therapeutics program in neurology and neuroinflammation.
Editorial note
Herantis is published because official investor and company materials confirm current leadership, Espoo operating footprint, and a clear therapeutics program in neurology and neuroinflammation.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Biologic Therapeutics Development
CNS Drug Development
Translational Neuroinflammation Research
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Biologic drug-development workflow
Clinical and translational program infrastructure
Therapeutics R&D systems
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
21 Mar 2026: Executive identity confirmed via official management disclosure.
21 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Herantis Pharma located?
- Herantis Pharma operates from Bertel Jungin aukio 1, FI-02600 Espoo, Finland, Espoo, Finland.
- Who runs Herantis Pharma?
- Herantis Pharma is led by Antti Vuolanto, CEO. Verified 21 Mar 2026.
- What does Herantis Pharma do?
- Herantis Pharma runs biologic therapeutics development, cns drug development, and translational neuroinflammation research in Espoo, Finland. Core capabilities: Biologic Therapeutics Development, CNS Drug Development, Translational Neuroinflammation Research.
Editorial context
Related technical briefs
Briefs that name Espoo as a covered market or city.